Dermapharm Executes Share Buyback Amid Strong Interest

Dermapharm Holding SE has successfully completed a public share buyback offer, acquiring 4,299,190 shares. This process ended on March 24, 2026. A total of 4,843,127 shares were tendered, surpassing the company’s buyback limit of 4,300,000 shares, equivalent to approximately 7.99% of its registered share capital. As the offer exceeded the intended number, acceptance was adjusted on a pro-rata basis, disregarding fractional shares.

The settlement is expected by April 2, 2026, through custodian banks linked to Clearstream Europe. The company plans to cancel the acquired treasury shares, which lack voting and dividend rights. Dermapharm’s action demonstrates strategic financial management, albeit amid limitations prohibiting offer distribution in certain jurisdictions.